AN2 Therapeutics (ANTX) Director Marks Lynn Receives 3,775-Share Award

What Happened
Marks Gilbert Lynn, a director of AN2 Therapeutics (ANTX), was issued 3,775 shares on 2026-04-10 as an award/compensation. The Form 4 reports an acquisition at $0.00 (total reported value $0) because the shares were issued in lieu of cash compensation rather than purchased on the open market.

Key Details

• Transaction date: 2026-04-10
• Transaction type/code: Award/Grant (Code A) — 3,775 shares issued @ $0.00 (reported value $0)
• Vesting: All shares vested immediately (per footnote)
• Shares owned after transaction: Not specified in the provided filing
• Footnote: Shares issued in lieu of cash compensation under the issuer’s non-employee director compensation policy; all shares vest immediately.
• Filing timeliness: Reported on 2026-04-10 (same-day filing; not indicated as late)

Context
This was a compensation award to a non-employee director rather than an open-market buy or sale. Such issuances are routine director pay and do not necessarily signal the director buying or selling based on company outlook. Immediate vesting means the director has full ownership of the shares upon issuance.